Skip to main content
. 2022 Dec 7;28:182–196. doi: 10.1016/j.omto.2022.12.002

Figure 4.

Figure 4

Verification of the effect of m-PPDCNPs in vitro gene silencing and combination medication

(A and B) Relative VEGF mRNA levels in HCT116 cells incubated with PPDCNPs (only miR-NC), Lipo-miR-190-Cy7，PPDCNPs (only miR-190-Cy7) or m-PPDCNPs (only miR-190-Cy7) for 24 h or 48 h as indicated by real-time PCR. β-Actin was used as the loading control in real-time PCR assay. N = 3. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 (t-test). (C and D) Luciferase activity in the Luci-HCT116 cells upon transfection with PPDCNPs (only miR-NC), Lipo-miR-190-Cy7, PPDCNPs (only miR-190-Cy7) or m-PPDCNPs (only miR-190-Cy7) for 24 h or 48h. N = 3. ∗∗ P < 0.01, ∗∗∗ P < 0.005 (t-test). Control: Cells incubated with free medium. (E and F) ELISA assay of secreted VEGF in HCT116 cells incubated with PPDCNPs (only miR-NC), Lipo-miR-190-Cy7, PPDCNPs (only miR-190-Cy7) or m-PPDCNPs (only miR-190-Cy7) for 24 h or 48 h, as indicated. N = 3. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 (t-test). (G andH) Western blot analysis and quantification of VEGF expression in HCT116 cells treated with PPDCNPs (only miR-NC), Lipo-miR-190-Cy7, PPDCNPs (only miR-190-Cy7) or m-PPDCNPs (only miR-190-Cy7) for 24 h or 48 h. (I) Proliferation profile of HCT116 cells treated with Lipo-miR-190-Cy7 and Dox with gradient concentration. N = 5. (J) Proliferation profile of HCT116 cells incubated with Dox, Lipo-miR-NC, Lipo-miR-190-Cy7, PPDCNPs (only miR-NC), Lipo-miR-190-Cy7, PPDCNPs (Dox and miR-NC), PPDCNPs or m-PPDCNPs for 0 h, 4 h, 12 h, 24 h or 48 h, as indicated. N=5.